期刊文献+

CNSI患者血浆中uPA及其受体(uPAR)的变化和临床意义

Clinical Significance of Detection of Changes of Plasma Urokinase-type Plasminogen Activator and its Receptor Levels in Patients with Central Nervous System Infection
下载PDF
导出
摘要 目的:研究中枢神经系统感染(CNSI)患者血浆中尿激酶型纤溶酶原激活物(uPA)及其受体(uPAR)的变化及意义。方法:收集我院2006年10月~2008年7月CNSI住院患者69例,将CNSI病例分为病毒性脑炎组、结核性脑膜炎组、化脓性脑膜炎组,并设立对照组。用双抗体夹心酶联免疫法检测所有CNSI病例血浆中uPA及其受体(uPAR)水平。结果:化脓性脑膜炎组、结核性脑膜炎组uPA及其受体(uPAR)水平明显高于病毒组及对照组(P<0.01),血浆uPAR浓度改变与uPA同步,但uPAR升高水平高于uPA。结论:血浆中uPA及其受体(uPAR)水平在化脓性脑膜炎、结核性脑膜炎中升高,可为化脓性脑膜炎、结核性脑膜炎、病毒性脑炎的鉴别诊断提供更多的实验室依据。 Objective To study the clinical significance of changes of expression of plasma urokinase-type plasminogen activator(uPA)and urokinase-type plasminogen activator receptor(uPAR)in patients with central nervous system infection(CNSI).Methods The expressions of plasma uPA and uPAR were detected with ELISA in 69 patients with various kinds of CNSI(viral encephalitis n=28,tuberculous meningitis n=18,and suppurative meningitis n=23)and 30 controls.Results The levels of plasma uPA and uPAR were significantly higher in patients with tuberculous and suppurative meningitis than those in the controls(P0.01).Conclusion The levels of plasma uPA and uPAR were significantly increased in patients with tuberculous and suppurative meningitis,but not in patients with viral encephalitis.It may supply more laboratory evidence for differential diagnosis of viral from bacterial CNS infections.
出处 《放射免疫学杂志》 CAS 2010年第3期334-337,共4页 Journal of Radioimmanology
关键词 尿激酶型纤溶酶原激活物 血浆 鉴别诊断 中枢神经系统感染 urokinase-type plasminogen activator(uPA) plasma differential diagnosis central nervous system infection(CNSI)
  • 相关文献

参考文献10

  • 1Kruger A, Soeltl R, Lutz V, et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urkinasetype plasminogen activator receptor(CD87) [ J]. Cancer Gene Thor, 2000, 7 (2) : 292-299.
  • 2Nakata S, ho K, Fujimori M, et al. Involvement of vascular endothelial growth factor and urokinase type plasminogen activitor receptor in microvessel invasion in human colorectal cancers[J]. Int J Carcer,1998, 79 (2) : 179-186.
  • 3Rasch MG, Lund IK, Almasi CE, et al. Intact and cleaved uPAR forms : diagnostic and prognostic value in cancer[ J]. Front Biosci, 2008, 1 ( 13 ) : 6752-6762.
  • 4Del Rosso M, Fibbi G, Pucci M, et al. The plasminogen activation system in inflammation[ J]. Front Biosci, 2008, 1 (13) : 4667-4686.
  • 5Zhang G, Eddy AA. Urokinase and its receptors in chronic kidney disease[J]. Front Biosci, 2008, 1(13) : 5462-5478.
  • 6Slot O, Brenner N, Locht H, et al. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders, increased concentrations in rheumatoid arthritis [ J ]. Cancer Res, 1998, 58(9) : 1843-1849.
  • 7陆新良,诸景辉,卢兴国,姒健敏.血浆尿激酶型纤溶酶原激活物及其受体在急性胰腺炎中的测定及意义[J].世界华人消化杂志,2005,13(6):803-805. 被引量:3
  • 8Bell WR. The fibrinolytic system in neoplasia [ J ]. Semin Thromb Hemostas, 1996, 22(3) : 459-471.
  • 9Westermarck J, Kanhari VM. Regulation of matrix metalloproteinase expression in tumor invasion[J]. FASEB J, 1999, 13(8) : 781-792.
  • 10Abrahan E, Margaret RG, Katherine K, et al. Urokinase type plasmingogen activator potentiates lipopolysaccharide induced neutrophil activation[J]. J Immunol, 2003, 170(11) : 5644-5651.

二级参考文献15

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部